These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12588472)

  • 21. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
    Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
    Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology and clinical experience with alosetron.
    Camilleri M
    Expert Opin Investig Drugs; 2000 Jan; 9(1):147-59. PubMed ID: 11060667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
    Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ischemic colitis during treatment with alosetron.
    Friedel D; Thomas R; Fisher RS
    Gastroenterology; 2001 Feb; 120(2):557-60. PubMed ID: 11159896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review article: clinical pharmacology of alosetron.
    Gunput MD
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alosetron and irritable bowel syndrome.
    Mayer EA; Bradesi S
    Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
    Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
    Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
    Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
    Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Zheng Y; Yu T; Tang Y; Xiong W; Shen X; Jiang L; Lin L
    PLoS One; 2017; 12(3):e0172846. PubMed ID: 28291778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
    Olden KW; Chey WD; Shringarpure R; Paul Nicandro J; Chuang E; Earnest DL
    Curr Med Res Opin; 2019 Mar; 35(3):461-472. PubMed ID: 30293448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
    Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM
    Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
    Ford AC; Brandt LJ; Young C; Chey WD; Foxx-Orenstein AE; Moayyedi P
    Am J Gastroenterol; 2009 Jul; 104(7):1831-43; quiz 1844. PubMed ID: 19471254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.
    Cremonini F; Nicandro JP; Atkinson V; Shringarpure R; Chuang E; Lembo A
    Aliment Pharmacol Ther; 2012 Sep; 36(5):437-48. PubMed ID: 22779693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
    Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
    Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
    Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?
    Andresen V; Hollerbach S
    Drug Saf; 2004; 27(5):283-92. PubMed ID: 15061683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.